Can't argue with any of that. Few probably understand that CBAI wrote off the entire cost of acquiring a 51% interest in Stellacure in the 1st quarter ($820K). So no longterm write off coming for that. I would assume if they acquire Biocells they will do the same thing. That's good for us investors because expectations are low right now for the financials and those kinds of actions will set us up to be profitable sooner. And also as I posted earlier, few probably have read the China deal which lays out minimum revenue (royalties) payments as part of the deal. So even if Newco (new AXMP sub), which has yet to be announced, fails to make there targets they have to cut us a predetermined check and the amount goes up each quarter. Plus, it's clear there is room to expand in China with this deal which could be huge for this company. All profit. Matt's job is not to manage the share price but to implement his business plan and strategy and that is what he is doing. This company could be a goldmine and I feel few here have that understanding/vision.
Don't worry about the mule going blind just load the wagon.
